Jeysen Yogaratnam

Dr. Jeysen Yogaratnam has more than 20 years of clinical and drug development experience with significant expertise in the design, execution, and interpretation of Phase 1-4 clinical trials across a range of therapeutic areas including chronic hepatitis B, C and D, influenza, HIV, and oncology. Dr. Yogaratnam has held roles of increasing responsibility and seniority which included leading clinical development programs at Aligos Therapeutics, Eiger Biopharmaceuticals, Janssen Pharmaceuticals, Vertex Pharmaceuticals and Bristol Myers Squibb. At Janssen Pharmaceuticals, Dr. Yogaratnam advanced a novel anti-HBV capsid assembly modulator from a first-in-human clinical trial to Phase 2b clinical trials. Dr. Yogaratnam received a PhD in Biological Sciences from University of Hull and an MBA from Massachusetts Institute of Technology. He completed his Diploma in Surgery from the Royal College of Surgeons of Edinburgh and earned his undergraduate medical degree from The Royal College of Surgeons in Ireland.